Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs. RESEARCH DESIGN AND METHODS: This was a 56-week, double-blind, placebo-controlled study in which 505 patients received standardized lifestyle intervention and were randomized 2:1 to NB or placebo. Coprimary end points were percent weight change and achievement of ≥5% weight loss. Secondary end points included achievement of HbA1c <7% (53 mmol/mol), achievement of weight loss ≥10%, and change in HbA1c, waist circumference, fasting blood glucose, and lipids. RESULTS: In the modified intent-to-treat population (54% female, 80% Caucasian, and mean age 54 years, weight 106 kg, BMI 37 kg/m2, and HbA1c 8.0% [64 mmol/mol]), NB resulted in significantly greater weight reduction (−5.0 vs. −1.8%; P < 0.001) and proportion of patients achieving ≥5% weight loss (44.5 vs. 18.9%, P < 0.001) compared with placebo. NB also resulted in significantly greater HbA1c reduction (−0.6 vs. −0.1% [6.6 vs. 1.1 mmol/mol]; P < 0.001), percent of patients achieving HbA1c <7% (53 mmol/mol) (44.1 vs. 26.3%; P < 0.001), and improvement in triglycerides and HDL cholesterol compared with placebo. NB was associated with higher incidence of nausea (42.3 vs. 7.1%), constipation (17.7 vs. 7.1%), and vomiting (18.3 vs. 3.6%). No difference was observed between groups in the incidence of depression, suicidal ideation, or hypoglycemia. CONCLUSIONS: NB therapy in overweight/obese patients with type 2 diabetes induced weight loss, which was associated with improvements in glycemic control and select cardiovascular risk factors and was generally well tolerated with a safety profile similar to that in patients without diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Even so, in subanalyses, persons losing more than 10% of weight at 1 year experienced a 21% reduction in the composite CVD outcome.734”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [734]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similar attenuation in weight loss in patients with vs without type 2 diabetes has been observed with other AOM, including orlistat,(44) naltrexone-bupropion,(45) and liraglutide 3.0 mg,(46) as well as with some behavioral interventions.(47, 48)”
From Semaglutide for the treatment of obesity (2023) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“In COR-Diabetes, naltrexone/bupropion yielded − 5% weight loss and − 0.6% HbA1c reductions [35].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [35]
In the citing paper
“Naltrexone plus bupropion extended-release reduces weight on average by ≈7% (≈5% placebo-subtracted) [51][52][53][54] and also more than either agent administered alone.55”
From Approach to Obesity Treatment in Primary Care: A Review (2024) · cites this paper as [52]
In the citing paper
“Other AOMs have yielded comparably smaller weight losses in patients with versus without type 2 diabetes [58].”
From The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities (2023) · cites this paper as [58]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Prevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010
Flegal, K. M., Carroll, M. D., Kit, B. K., & Ogden, C. L. (2012) · JAMA · doi:10.1001/jama.2012.39 · Cited by 5,385
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354
Christiane, Druml, Wolzt, & Pleiner (2001) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 3,419
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Central nervous system control of food intake and body weight
Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S., & Schwartz, M. W. (2006) · Nature · doi:10.1038/nature05026 · Cited by 2,503 · cited 2×
“Furthermore, naltrexone and bupropion therapy are believed to influence the mesolimbic dopaminergic reward system,which canmodulate reward behaviors such as food intake (14,15).”
Background
Research works printed but not linked: 1
- Sinnayah, 2007, Bupropion and naltrexone interact synergistically to decrease food intake in mice, Obesity (Silver Spring), 15, A179
Cited by
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationDavies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Bray, G. A., Frühbeck, G., Ryan, D. H., & Wilding, J. P. H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00271-3 · Cited by 1,036
Khera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., Loomba, R., Camilleri, M., & Singh, S. (2016) · JAMA · doi:10.1001/jama.2016.7602 · Cited by 865
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2016) · Endocrine Practice · doi:10.4158/ep151126.cs · Cited by 878
“These agents improve BP and lipids, prevent progression to diabetes during trial periods, and improve glycemic control and lipids in patients with T2D (43-60).”
BackgroundThe science of obesity management: an endocrine society scientific statement
Bray, G. A., Heisel, W. E., Afshin, A., Jensen, M. D., Dietz, W. H., Long, M., Kushner, R. F., Daniels, S. R., Wadden, T. A., Tsai, A. G., et al. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00253 · Cited by 812
Garvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N. N., Bunck, M. C., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01200-x · Cited by 792
Contemporary medical, device, and surgical therapies for obesity in adults
Perdomo, C. M., Cohen, R. V., Sumithran, P., Clément, K., & Frühbeck, G. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02403-5 · Cited by 738
Food cue reactivity and craving predict eating and weight gain: A meta-analytic review
Boswell, R. G., & Kober, H. (2016) · Obesity Reviews · doi:10.1111/obr.12354 · Cited by 703
Gadde (2018) · doi:10.1016/j.jacc.2017.11.011 · Cited by 626
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598
Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
Lingvay, I., Sumithran, P., Cohen, R. V., & le Roux, C. W. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01919-x · Cited by 581
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2018) · Endocrine Practice · doi:10.4158/cs-2017-0153 · Cited by 502
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101882 · Cited by 462
Obesity as a multisystem disease: Trends in obesity rates and obesity‐related complications
Sarma, S., Sockalingam, S., & Dash, S. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14290 · Cited by 435
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435
“These agents improve BP and lipids, prevent progression to diabetes during trial periods, and improve glycemic control and lipids in patients with T2D (46-63).”
BackgroundSignaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
Lingvay, I., Cohen, R. V., Roux, C. W. L., & Sumithran, P. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01210-8 · Cited by 433
Current pharmacotherapy for obesity
Srivastava, G., & Apovian, C. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.122 · Cited by 397
Progress and challenges in anti-obesity pharmacotherapy
Bessesen, D. H., & Van Gaal, L. F. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30236-x · Cited by 347
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
Grunvald, E., Shah, R., Hernaez, R., Chandar, A. K., Pickett-Blakely, O., Teigen, L. M., Harindhanavudhi, T., Sultan, S., Singh, S., & Davitkov, P. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.08.045 · Cited by 347
“79,81,82 Although not formally tested for its effect on mood as a primary outcome in these trials, a small open-label study in women with major depressive disorder showed signi fi cant improvement in depressive symptoms that were sustained at 24 weeks of therapy with naltrexone-bupropion ER at…”
BackgroundMethodLong-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak, Y. J., & Lee, S. Y. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00422-w · Cited by 343
Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging
Ng, A. C. T., Delgado, V., Borlaug, B. A., & Bax, J. J. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00465-5 · Cited by 331
Ard, J., Fitch, A., Fruh, S., & Herman, L. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01710-0 · Cited by 297
“…30 (or C 27 with controlled hypertension and/or dyslipidemia) to 45 kg/m2 (NB32; placebo) 66%; 43% (p\ 0.001) (NB32; placebo) 42%; 20% (p\ 0.001) NR Hollander et al., 2013: placebo-controlled, double-blind, randomized, 56-week trial of naltrexone-bupropion (NB32) QD in patients with BMI C 27 and B…”
InfluentialGarber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice · doi:10.4158/cs-2018-0535 · Cited by 297
“These agents can improve BP and lipids, prevent progression to diabetes, and improve glycemic control and lipids in patients with T2D (48-65).”
BackgroundShi, Q., Wang, Y., Hao, Q., Vandvik, P. O., Guyatt, G., Li, J., Chen, Z., Xu, S., Shen, Y., Ge, L., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01640-8 · Cited by 279
RetractedHudgel, D. W., Patel, S. R., Ahasic, A. M., Bartlett, S. J., Bessesen, D. H., Coaker, M. A., Fiander, P. M., Grunstein, R. R., Gurubhagavatula, I., Kapur, V. K., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1326st · Cited by 266
Medications for Obesity: A Review
Gudzune, K. A., & Kushner, R. F. (2024) · JAMA · doi:10.1001/jama.2024.10816 · Cited by 263
Pharmacotherapy of obesity: available medications and drugs under investigation.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s008 · Cited by 244
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s008 · Cited by 244
Cefalu, W. T., Bray, G. A., Home, P. D., Garvey, W. T., Klein, S., Pi-Sunyer, F. X., Hu, F. B., Raz, I., Van Gaal, L., Wolfe, B. M., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1081 · Cited by 243
Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss
Billes, S. K., Sinnayah, P., & Cowley, M. A. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.04.004 · Cited by 242
Body Weight Considerations in the Management of Type 2 Diabetes
Apovian, C. M., Okemah, J., & O’Neil, P. M. (2019) · Advances in Therapy · doi:10.1007/s12325-018-0824-8 · Cited by 239
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s008 · Cited by 236
Semaglutide for the treatment of obesity
Chao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.12.008 · Cited by 227
2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Hur, K. Y., Moon, M. K., Park, J. S., Kim, S.-K., Lee, S.-H., Yun, J.-S., Baek, J. H., Noh, J., Lee, B.-W., Oh, T. J., et al. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0156 · Cited by 226
“If patients with T2DM and BMI ≥25 kg/m(2) (class I) fail to lose weight with diet, physical activity, and behavior counseling, anti-obesity medications can be considered (Others, Limited) [46-48].”
BackgroundWeight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
Van Gaal, L., & Scheen, A. (2015) · Diabetes Care · doi:10.2337/dc14-1630 · Cited by 221
“It is interesting to note that the reductions in HbA1c observed with lorcaserin are equal to or higher than those observed with other antiobesity agents, such as phentermine plus topiramate and NB, despite a smaller amount of weight loss (71,73,80).”
BackgroundResultAmerican Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s008 · Cited by 213
Drug safety evaluation of naltrexone/bupropion for the treatment of obesity
Verpeut, J. L., & Bello, N. T. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.909405 · Cited by 202
Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes
Scheen, A. J., & Van Gaal, L. F. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70004-x · Cited by 190
Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review
Tak, Y. J., & Lee, S. Y. (2021) · The World Journal of Men's Health · doi:10.5534/wjmh.200010 · Cited by 184
“I (n=1,742), COR-II (n=1,496), and COR-BMOD (Behavior MODification) (n=793) trials included patients with a BMI ≥27 kg/m2, at least one weight-related comorbid condition (i.e., hypertension [HTN]), and COR-DM (Diabetes Mellitus) [45-48].”
MethodInfluentialEvolution of pharmacological obesity treatments: focus on adverse side‐effect profiles
Krentz, A. J., Fujioka, K., & Hompesch, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12657 · Cited by 168
“Improvements in glycaemic control and selected cardiovascular risk factors have been demonstrated with naltrexone/bupropion in patients with type 2 diabetes [126].”
BackgroundSelf-citationSaunders, K. H., Umashanker, D., Igel, L. I., Kumar, R. B., & Aronne, L. J. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.08.010 · Cited by 159
Kim, K.-K., Haam, J.-H., Kim, B. T., Kim, E. M., Park, J. H., Rhee, S. Y., Jeon, E., Kang, E., Nam, G. E., Koo, H. Y., et al. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23016 · Cited by 158
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s008 · Cited by 158
New insights into the treatment of obesity
Blüher, M., Aras, M., Aronne, L. J., Batterham, R. L., Giorgino, F., Ji, L., Pietiläinen, K. H., Schnell, O., Tonchevska, E., & Wilding, J. P. H. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15077 · Cited by 158
“The Contrave Obesity Research (COR) clinical trial programme assessed the efficacy and safety of the drug combination.(50,51,59,60) In the COR-I(50) and COR-II(51) trial, participants received a 32/360 mg daily dose of the combination adjunct to mild hypocaloric diet and exercise or lifestyle modification advice, resp…”
MethodShi, Q., Wang, Y., Hao, Q., Vandvik, P. O., Guyatt, G., Li, J., Chen, Z., Xu, S., Shen, Y., Ge, L., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00351-9 · Cited by 155
Centrally Acting Agents for Obesity: Past, Present, and Future
Coulter, A. A., Rebello, C. J., & Greenway, F. L. (2018) · Drugs · doi:10.1007/s40265-018-0946-y · Cited by 151
“Cardio-metabolic risk factors improved, and side effects reflected those seen in the other Phase III studies [43].”
Self-citationWeight management in patients with type 1 diabetes and obesity
Mottalib, A., Kasetty, M., Mar, J. Y., Elseaidy, T., Ashrafzadeh, S., & Hamdy, O. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0918-8 · Cited by 149
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc19-s008 · Cited by 203
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc20-s008 · Cited by 173
Comprehensive Review of Current and Upcoming Anti-Obesity Drugs
Son, J. W., & Kim, S. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0258 · Cited by 134
Gender-related Differences in Food Craving and Obesity.
Hallam, J., Boswell, R. G., DeVito, E. E., & Hedy Kober, A. (2016) · PubMed Central · Cited by 225
Obesity and Weight Loss in Idiopathic Intracranial Hypertension: A Narrative Review
Subramaniam, S., & Fletcher, W. A. (2016) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000448 · Cited by 152
Nadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.017 · Cited by 141
Obesity and cardiovascular risk
Kotsis, V., Jordan, J., Micić, D., Finer, N., Leitner, D. R., Toplak, H., Tokgözoğlu, L. S., Athyros, V. G., Elisaf, M., Filippatos, T. D., et al. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001730 · Cited by 161
Singh, A. K., & Singh, R. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1698291 · Cited by 130
Wadden, T. A., Chao, A. M., Moore, M., Tronieri, J. S., Gilden, A., Amaro, A., Leonard, S., & Jakicic, J. M. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00534-z · Cited by 129
“Other AOMs have yielded comparably smaller weight losses in patients with versus without type 2 diabetes [58].”
BackgroundNovel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angelidi, A. M., Belanger, M. J., Kokkinos, A. D., Koliaki, C. C., & Mantzoros, C. S. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab034 · Cited by 149
Grams, J. M., & Garvey, W. T. (2015) · Current Obesity Reports · doi:10.1007/s13679-015-0155-x · Cited by 145
Safety and tolerability of new-generation anti-obesity medications: a narrative review
Patel, D. K., & Stanford, F. C. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1435129 · Cited by 131
Pharmacotherapy for the management of obesity
Patel, D. K. (2015) · Metabolism · doi:10.1016/j.metabol.2015.08.001 · Cited by 128
Updates on obesity pharmacotherapy
Velazquez, A., & Apovian, C. M. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13542 · Cited by 132
Long-term effects of weight-reducing drugs in people with hypertension
Siebenhofer, A., Jeitler, K., Horvath, K., Berghold, A., Posch, N. A. S., Meschik, J., & Semlitsch, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub4 · Cited by 135
Drug treatment of obesity: Current status and future prospects
Kakkar, A. K., & Dahiya, N. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.01.005 · Cited by 113
Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done?
Brown, A., Guess, N., Dornhorst, A., Taheri, S., & Frost, G. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13009 · Cited by 113
Aras, M., Tchang, B. G., & Pape, J. (2021) · Nursing Clinics of North America · doi:10.1016/j.cnur.2021.07.008 · Cited by 132
A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome
Abdalla, M. A., Deshmukh, H., Atkin, S. L., & Sathyapalan, T. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820938305 · Cited by 132
Approach to Obesity Treatment in Primary Care: A Review
Yanovski, S. Z., & Yanovski, J. A. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.8526 · Cited by 103
Kreider, K. E. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0231-1 · Cited by 117
“There is also some data that bupropion may induce weight loss in people with diabetes and MDD, potentially leading to improved cardiovascular risk profile [29].”
BackgroundPharmacological approaches to the prevention of type 2 diabetes mellitus
Majety, P., Orquera, F. A. L., Edem, D., & Hamdy, O. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1118848 · Cited by 149
“COR-Diabetes study (57) including subjects with T2DM reported improvements in glucose homeostasis, resulting in A1C reduction of 0.”
BackgroundMcGowan, B., Ciudin, A., Baker, J. L., Busetto, L., Dicker, D., Frühbeck, G., Goossens, G. H., Monami, M., Sbraccia, P., Martinez-Tellez, B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03978-z · Cited by 100
Khera, R., Pandey, A., Chandar, A. K., Murad, M. H., Prokop, L. J., Neeland, I. J., Berry, J. D., Camilleri, M., & Singh, S. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.12.024 · Cited by 90
Best Practices in the Management of Overweight and Obesity
Tchang, B. G., Saunders, K. H., & Igel, L. I. (2020) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.08.018 · Cited by 111
Health Benefits of Long-Term Weight-Loss Maintenance
Rueda‐Clausen, C. F., Ogunleye, A. A., & Sharma, A. M. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034434 · Cited by 103
Fujioka, K., Plodkowski, R. A., O'Neil, P. M., Gilder, K. M., Walsh, B., & Greenway, F. L. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.67 · Cited by 90
Self-citationObesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges
Vilarrasa, N., José, P. S., Rubio, M. Á., & Lecube, A. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s223618 · Cited by 109
O'Neil, P. M., Miller‐Kovach, K., Tuerk, P. W., Becker, L. E., Wadden, T. A., Fujioka, K., Hollander, P. L., Kushner, R. F., Garvey, W. T., Rubino, D., et al. (2016) · Obesity · doi:10.1002/oby.21616 · Cited by 89
Self-citationManagement of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome
Srikanth, S., & DEEDWANIA, P. C. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0683-0 · Cited by 98
New Medications for Treatment of Obesity: Metabolic and Cardiovascular Effects
Pucci, A. B. F., & Finer, N. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.11.010 · Cited by 86
Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults
Hwang, J. H., Laiteerapong, N., Huang, E. S., & Kim, D. D. (2025) · JAMA Health Forum · doi:10.1001/jamahealthforum.2024.5586 · Cited by 77
Naltrexone Extended-Release Plus Bupropion Extended-Release for Treatment of Obesity
Yanovski, S. Z., & Yanovski, J. A. (2015) · JAMA · doi:10.1001/jama.2015.1617 · Cited by 80
(2016) · PubMed Central · Cited by 77
Current and emerging medications for overweight or obesity in people with comorbidities
Fujioka, K. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12502 · Cited by 76
“Naltrexone/bupropion also improved certain cardiovascular risk markers vs placebo (HbA1c, weight circumference, HDL cholesterol and triglycerides) in people with diabetes [63].”
BackgroundSelf-citationOnakpoya, I., Lee, J. J., Mahtani, K. R., Aronson, J. K., & Heneghan, C. J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14210 · Cited by 82
Volpe, M., & Gallo, G. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1136340 · Cited by 102
Tolerability and Safety of the New Anti-Obesity Medications
Hainer, V., & Aldhoon-Hainerová, I. (2014) · Drug Safety · doi:10.1007/s40264-014-0206-3 · Cited by 81
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Pan, X., Tan, B. C., Chin, Y. H., Lee, E. C. Z., Kong, G., Chong, B., Kueh, M. T. W., Khoo, C. M., Mehta, A., Majety, P., et al. (2024) · Obesity · doi:10.1002/oby.24002 · Cited by 85
Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update
Pedersen, S. D., Manjoo, P., Dash, S., Jain, A., Pearce, N., & Poddar, M. (2025) · Canadian Medical Association Journal · doi:10.1503/cmaj.250502 · Cited by 78
Papamargaritis, D., le Roux, C. W., Holst, J. J., & Davies, M. J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvac176 · Cited by 73
Markovic, T., Proietto, J., Dixon, J. B., Rigas, G., Deed, G., Hamdorf, J. M., Bessell, E., Kizirian, N. V., Andrikopoulos, S., & Colagiuri, S. (2022) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2022.08.003 · Cited by 80
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s008 · Cited by 160
Long-term effects of weight-reducing drugs in people with hypertension
Siebenhofer, A., Winterholer, S., Jeitler, K., Horvath, K., Berghold, A., Krenn, C., & Semlitsch, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub5 · Cited by 70
Rosenblit, P. D. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0412-7 · Cited by 75
“Phentermine/topiramate has also been shown to reduce LDL-C levels, while naltrexone/bupropion has been linked to a reduction or no change in LDL-C levels [118–128].”
Background
Metadata
- Authors
- Hollander, P., Gupta, A. K., Plodkowski, R., Greenway, F., Bays, H., Burns, C., Klassen, P., Fujioka, K., & for the COR-Diabetes Study Group
- Affiliations
- Baylor University Medical Center (US)
- Pennington Biomedical Research Center (US)
- Scripps Clinic (US)
- Louisville Metabolic and Atherosclerosis Research Center (US)
- Orexigen Therapeutics (United States) (US)
- Corresponding author
- Hollander, Priscilla
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-11-13
- Volume
- 36
- Issue
- 12
- Pages
- 4022-4029
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3836105
- OpenAlex
- W2020982355
- Cited by
- 501
- References
- 39
- Citations by year
- 2026: 29 · 2025: 50 · 2024: 56 · 2023: 51 · 2022: 35 · 2021: 47 · 2020: 34 · 2019: 27 · 2018: 34 · 2017: 40 · 2016: 42 · 2015: 43 · 2014: 12 · 2013: 1
- FWCI
- 23.98
- Type
- journal article
- Language
- en
- Update notices
- correction (2014-02-01)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- naltrexone/bupropion, combination therapy, type 2 diabetes, obesity, overweight, weight loss, glycemic control, HbA1c, triglycerides, HDL cholesterol, nausea, constipation, vomiting, antidepressant side effects, cardiovascular risk factors, lifestyle intervention, drug safety, drug efficacy, suicidal ideation, hypoglycemia
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Body Weight, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Naltrexone, Narcotic Antagonists, Obesity, Retrospective Studies, Risk Factors, Weight Loss, Bupropion, Treatment Outcome, Antidepressive Agents, Second-Generation, Overweight, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.